Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: a European MCL intergroup studyChristiane Pott, Martin Dreyling, Eva Hoster et al.|Blood|2009Cited by 269
Dose-Reduced Versus Standard Conditioning Followed by Allogeneic Stem-Cell Transplantation for Patients With Myelodysplastic Syndrome: A Prospective Randomized Phase III Study of the EBMT (RICMAC Trial)Nicolaus Kröger, Théo de Witte, Simona Iacobelli et al.|Journal of Clinical Oncology|2017Cited by 248
A non-antibiotic-disrupted gut microbiome is associated with clinical responses to CD19-CAR-T cell cancer immunotherapyChristoph K. Stein‐Thoeringer, Eran Elinav, Swaminathan P. Iyer et al.|Nature Medicine|2023Cited by 226
ESMO Guidelines consensus conference on malignant lymphoma 2011 part 1: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL)Michele Ghielmini, Markus Raderer, Umberto Vitolo et al.|Annals of Oncology|2012Cited by 218
Analysis of Risk Factors for Outcomes After Unrelated Cord Blood Transplantation in Adults With Lymphoid Malignancies: A Study by the Eurocord-Netcord and Lymphoma Working Party of the European Group for Blood and Marrow TransplantationCelso Arrais‐Rodrigues, Vanderson Rocha, Guillermo Sanz et al.|Journal of Clinical Oncology|2008Cited by 202